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Abstract
Recently BRCA1 has been implicated in the regulation of gene expression from the X
chromosome. In this study the influence of BRCA1 on expression of X chromosome genes was
investigated. Complementary DNA microarrays were used to compare the expression levels of X
chromosome genes in 18 BRCA1-associated ovarian cancers to those of the 13 "BRCA1-like" and
14 "BRCA2-like" sporadic tumors (as defined by previously reported expression profiling).
Significance was determined using parametric statistics with P < 0.005 as a cutoff. Forty of 178 total
X-chromosome transcripts were differentially expressed between the BRCA1-associated tumors
and sporadic cancers with a BRCA2-like molecular profile. Thirty of these 40 genes showed higher
mean expression in the BRCA1-associated samples including all 11 transcripts that mapped to
Xp11. In contrast, four of 178 total X chromosome transcripts showed significant differential
expression between BRCA1-associated and sporadic tumors with a BRCA1-like molecular profile.
All four mapped to Xp11 and showed higher mean expression in BRCA1-associated tumors. Re-
expression of BRCA1 in HCC1937 BRCA1-deficient breast cancer cell resulted in the repression
of 21 transcripts. Eleven of the 21 (54.5%) transcripts mapped to Xp11. However, there was no
significant overlap between these Xp11 genes and those found to be differentially expressed
between BRCA1-associated and sporadic ovarian cancer samples. These results demonstrate that
BRCA1 mediates the repression of several X chromosome genes, many of which map to the Xp11
locus.
Introduction
The mechanisms by which mutations in BRCA1 and
BRCA2 tumor suppressor genes lead to carcinogenesis are
incompletely understood. It remains to be established
whether pathways involved in BRCA1 and BRCA2-associ-
ated tumorigenesis are also altered in sporadic cancers.
Two recent reports demonstrated that BRCA1 and BRCA2-
associated tumors have distinct expression profiles in
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both breast [1] and ovarian [1,2] cancers. With respect to
ovarian cancers, two additional novel patterns of gene
expression were observed. First, the same set of genes that
distinguished BRCA1 and BRCA2-associated tumors also
segregated the sporadic (not BRCA1 or BRCA2-associated)
ovarian cancers into 2 subgroups consisting of "BRCA1-
like" and "BRCA2-like" gene expression profiles. This
observation lends support to the hypothesis that the same
or similar dichotomous molecular pathways are affected
in major subgroups of both hereditary and sporadic ovar-
ian tumors. Second, a disproportionate number of genes
located on the Xp11 locus showed statistically significant
higher expression in the BRCA1-associated tumors when
compared to sporadic tumors. Related to this observation,
Ganesan and colleagues recently demonstrated that
BRCA1 colocalizes with XIST RNA covering the inactive X
chromosome [3]. These investigators showed that repres-
sion of BRCA1 led to the increased expression of a green
fluorescent protein (GFP) transgene targeted to the inac-
tive X chromosome. However, it remains unknown
whether BRCA1 mediates any changes in expression of
normal X chromosome genes and whether any such
changes are global (affecting the entire X chromosome) or
specific to certain genes.
The goal of this study was to investigate further the influ-
ence of BRCA1 on the expression of transcripts mapped to
the X chromosome. For this purpose the BRCA-associated
and sporadic ovarian cancer gene expression data set was
analyzed with respect to the expression of 178 transcripts
mapped to the X chromosome. Additional in vivo and in
vitro experiments employing an X chromosome enriched
cDNA microarray were also performed to further evaluate
the expression patterns of X chromosome genes in a more
comprehensive manner.
Materials and Methods
Comparison of gene expression between BRCA-linked and 
sporadic ovarian cancers
The first part of this investigation consisted of a de novo
analysis of the large publicly available data set generated
by previous microarray experiments with respect to the
178 X chromosome specific genes [2]. Thus, the descrip-
tion of tumor samples used, BRCA1 and BRCA2 genotyp-
ing, tissue processing, and RNA extraction and
amplification, and microarray technique were previously
published [2]. In addition, detailed protocols describing
RNA amplification and microarray hybridization meth-
ods are available at http://nciarray.nci.nih.gov/reference
(under "Alternative Methods and Protocols").
Use of an X-chromosome enriched cDNA microarray for 
evaluating gene expression differences in BRCA1-
associated and sporadic ovarian cancers
For the second part of this investigation a recently devel-
oped cDNA microarray enriched in X chromosome tran-
scripts was used. The developmental rationale and
approach for this cDNA microarray are described in detail
elsewhere [4]. The X-enriched microarray chip used in this
investigation consisted of 5,296 features of which 2,879
mapped to the X chromosome. For the purposes of this
investigation analysis was limited to only the X chromo-
some features. Since the cDNAs on this array had not been
"sequence-verified" prior to spotting, the cDNA clones for
all genes found to be differentially expressed between
tumor samples and in cell line experiments were
sequenced to ensure positive identification of the tran-
scripts. Those transcripts for which PCR amplification did
not result in a product or multiple bands were identified
were eliminated from the final analysis.
Adenovirus-Mediated BRCA1 expression in HCC1937 cells
Tissue culture techniques and adenoviral infection of
HCC1937 cells was performed as described previously
[5]. Briefly, cells were plated 24 h before the infection at a
density 7 x 105 cells per 100 mm plate. The cells were
infected at 250 plaque-forming units per cell with adeno-
virus encoding full-length human BRCA1 or green fluores-
cent protein (GFP) cDNAs (the latter used as an irrelevant
infection control). Twenty-four hours later cells were har-
vested and RNA was purified using Trizol Reagent (Life
Technologies, Inc.) according to manufacturer's
instruction.
Experiments employing cDNA microarrays
In studies evaluating gene expression differences between
ovarian tumor samples using the X-enriched cDNA micro-
arrays, combined RNA from 10 human cell lines (Strata-
gene, La Jolla, CA) was used as the reference RNA. In
studies involving the HCC1937 cell line, gene expression
in BRCA1 virally infected cells was directly compared to
that of GFP infected controls.
The logarithmic expression ratios for the spots on each
array were normalized by subtracting the median logarith-
mic ratio for the same array. Data were filtered to exclude
spots with a size of less than 25 µm, an intensity of less
than two times background, or less than 300 units in both
red and green channels and to exclude any poor quality or
missing spots. In addition, any features found to be miss-
ing in greater than 20% of the arrays were not included in
the analysis. Statistical comparison between tumor groups
was performed with the "BRB Array Tools" software http:/
/linus.nci.nih.gov/~brb/tool.htm, consisting of a modi-
fied F test with P < 0.005 considered statistically signifi-
cant. This stringent P value was selected in lieu of theJournal of Translational Medicine 2004, 2:32 http://www.translational-medicine.com/content/2/1/32
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Bonferroni correction for multiple comparisons, which
was deemed excessively restrictive. For microarray experi-
ments involving the HCC1937 cells infected with BRCA1
or GFP the geometric mean of BRCA1:GFP expression
ratio from two separate microarray experiments was used.
Genes exhibiting a mean expression ratio change of two-
fold or greater were considered significant.
Quantitative RT-PCR
1 µg of total RNA was reverse transcribed in 50 µl reaction
and 5 µl of cDNA was then used for PCR reaction accord-
ing to Applied Biosystems technical manual. Separate
reaction of the same samples with β-actin was performed
for normalization purposes. The difference in threshold
number of cycles between the ARAF1 and β-actin was then
calculated and converted into real fold difference. All
measurements were done in triplicates and the results
were averaged. Probes for ARAF1 and β-actin were pur-
chased from Applied Biosystems Inc.
Results
It was previously shown that when compared to sporadic
cancers BRCA1-associated ovarian tumors were character-
ized by higher mean expression levels of genes mapped to
Xp11 [2]. This observation was confirmed when consider-
ing all genes mapped to the X chromosome (Fig. 1A).
Eleven of the 178 X chromosome mapped transcripts were
differentially expressed between the BRCA1-associated
and sporadic cancers (P < 0.005). Of these 11 transcripts,
six (55%) were located on Xp11. Because the sporadic
tumors could be divided into subgroups with "BRCA1-
and BRCA2-like" expression profiles [2], one may antici-
pate differences in the expression levels of genes mapped
to Xp11 when comparing each of these sporadic cancer
subgroups to the BRCA1-associated tumors. The expres-
sion levels of X chromosome genes in the 18 BRCA1-asso-
ciated cancers was compared to those of the 13 BRCA1-
like and 14 BRCA2-like sporadic tumors (Fig.
1A,1B,1C,1D). Only 4 genes showed significant differen-
tial expression between the BRCA1-associated and the
sporadic tumors with a BRCA1-like molecular profile (Fig.
1B). All 4 mapped to Xp11 and showed higher mean
expression in BRCA1-associated tumors. In contrast, 40 of
the 178 X-chromosome transcripts were differentially
expressed between the BRCA1-associated tumors and spo-
radic cancers with a BRCA2-like molecular profile (Fig. 1C
top panel). Thirty of the 40 transcripts showed higher
mean expression in the BRCA1-associated samples includ-
ing all 11 genes that mapped to Xp11 (Fig. 1C top panel).
These data suggest that BRCA1 may be involved in the reg-
ulation of gene expression from the X-chromosome. Fur-
thermore, there appears to be a role for BRCA1 in
suppressing the expression of several genes mapped to the
Xp11 locus that were all higher expressed in BRCA1-asso-
ciated tumors. This pattern of expression was observed
when the BRCA1-associated samples were compared to all
sporadic cancers regardless of their expression profile
characterization as BRCA1- or BRCA2-like.
The significance of this differential pattern of gene expres-
sion between the BRCA1-associated and sporadic cancers
is unclear at this time. However, higher expression from
Xp11 may be related to the earlier age of presentation of
epithelial ovarian cancers in BRCA1 mutation carriers
compared to tumors in BRCA2 mutation carriers and
patients with sporadic ovarian cancer [6]. This observa-
tion cannot be solely explained by an earlier occurrence of
a "second hit" as modeled by Knudson's two-hit hypoth-
esis [7] because the age of presentation of ovarian cancer
in BRCA2 tumors is no different than that observed in
patients with sporadic epithelial ovarian cancers [2,6],
thus indicating a BRCA1-specific effect on the age of
presentation.
In order to confirm and expand on the above noted differ-
ences in gene expression between BRCA1-associated and
sporadic tumors, an X-chromosome enriched cDNA
microarray was used [4]. Due to the limited availability of
resources this cDNA microarray was used to evaluate gene
expression in a representative subset of 9 BRCA1-associ-
ated and 8 sporadic tumors. The sporadic tumors were
selected from the subgroup with a "BRCA2-like profile" as
these samples showed more robust differences in X chro-
mosome gene expression in the above noted experiments
using our conventional cDNA microarray (Fig. 1B and
1C). Twenty-one transcripts showed significant differen-
tial expression between the BRCA1-associated and spo-
radic tumors with a BRCA2-like profile (P < 0.005).
Consistent with our earlier findings and despite the
smaller number of samples used for this comparison, the
majority of transcripts exhibited higher mean expression
in BRCA1-associated samples including all but one of the
transcripts located on Xp11 (Fig. 1D). This pattern of
expression was confirmed using quantitative RT-PCR of
the ARAF1 gene in a representative sample of BRCA1-asso-
ciated and sporadic ovarian cancer samples (Fig. 2).
We next sought to determine if differences in X chromo-
some gene expression between BRCA1-associated and
sporadic tumors were directly mediated by BRCA1 as
oppose to other, possibly confounding, features of these
tumors. The HCC1937 breast cancer cells that are either
homozygous or hemizygous for the BRCA15382insC
mutation were used as a model. Gene expression in
HCC1937 cells following virally mediated expression of
wild-type BRCA1 was compared to gene expression fol-
lowing viral infection of GFP which was employed as an
irrelevant infection control. Prior to using the X-chromo-
some enriched array, the validity of this approach was
tested using a 7.5 K microarray whose features includedJournal of Translational Medicine 2004, 2:32 http://www.translational-medicine.com/content/2/1/32
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X chromosome gene expression differences BRCA1-associated (B followed by a number) and sporadic (C followed by a  number) ovarian cancers (P < 0.005) Figure 1
X chromosome gene expression differences BRCA1-associated (B followed by a number) and sporadic (C followed by a 
number) ovarian cancers (P < 0.005). Genes are shown as hierarchical clusters (using centered correlation and average link-
age), samples were not clustered. The red and green color intensities represent expression levels shown as standard normal 
deviation (Z score) values from each gene's mean expression level (represented as black) across all compared tumor samples. 
The symbol for each gene is followed by the I.M.A.G.E. clone number of the corresponding cDNA spotted on the array. A. 
Genes differentially expressed between BRCA1-associated tumors and all sporadic samples. B. Genes differentially expressed 
between BRCA1-associated cancers and sporadic tumors characterized as "BRCA1-like" based on gene expression profile as 
described in reference 2. C. Genes differentially expressed between BRCA1-associated tumors and sporadic cancers charac-
terized as "BRCA2-like" based on gene expression profile as described in reference 2. D. An X chromosome enriched cDNA 
microarray was used to further investigate gene expression differences among a subset of BRCA1-associated and BRCA2-like 
sporadic tumors. The results of these experiments confirmed the findings observed above in (C).
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BRCA1. This preliminary experiment demonstrated that
viral infection did in fact result in a 3.4 fold higher BRCA1
expression compared to the GFP control (data not
shown). BRCA1 expression was also demonstrated using
Western blotting which confirmed BRCA1 protein expres-
sion following viral infection (Fig. 3).
Twenty-one X-chromosome transcripts demonstrated at
least a two-fold mean expression change across two inde-
pendent experiments following BRCA1 infection. It is
notable that all 21 transcripts (representing 16 unigene
clusters) showed decreased expression following BRCA1
transfection with a median repression of 2.4 fold. This
uniform repression is particularly significant because
median based normalization of logarithmic ratios was
employed in microarray data analysis. Thus, the median
log expression ratio for all 5,296 features on the array was
adjusted to zero (corresponding to an expression ratio of
1.0). Following this median based normalization, the
median log expression ratio of the transcripts mapped to
the X chromosome (2,879 of the total 5,296 features on
the array) was also very close to zero (median log2 ratio =
0.016 corresponding to an expression ratio of 1.01). Thus,
the observed down regulation of genes does not appear to
Quantitative RT-PCR evaluation of ARAF1 expression confirms cDNA microarray data Figure 2
Quantitative RT-PCR evaluation of ARAF1 expression confirms cDNA microarray data. Average of three RT-PCR repeats for 
each sample is shown on top left panel. ARAF1 expression levels derived by cDNA microarray relative to universal reference 
RNA is shown in the bottom left panel. Mean expression levels are graphed to the right; error bars represent standard error 
of mean.
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be a result of the X-enriched composition of the cDNA
microarray used in these experiments nor can it be
explained in terms of a global down regulation of all X
chromosome transcripts. Rather, the observed repression
appears to be a specific effect of BRCA1 expression on
these 21 transcripts.
Eleven of the 21 (52.4%) transcripts map to Xp11 and
represent 8 unigene clusters (Table 1). The most highly
repressed (11.6-fold) transcript was that of LOC139135
(Hs.160594) whose protein product contains a PAS
domain and is weakly similar to the circadian locomoter
output cycles kaput (CLOCK) protein of human and sev-
eral other organisms. The PAS domain is a highly con-
served motif essential for sensing changes in a variety of
different environmental conditions including light, oxy-
gen tension and redox potential [8,9]. HIF-1 alpha and
EPAS-1, two other PAS containing proteins, are upregu-
lated in a number of human tumors and play an impor-
tant role in angiogenesis by stimulating VEGF expression
[9-11]. LOC139135 deserves additional investigation of
its role as a possible protooncogene subject to regulation
by BRCA1.
Two transcripts representing the same unigene cluster, Hs.
99070, showed greater than 8 fold repression following
BRCA1 expression in HCC1937 cells (Table 1). In addi-
tion, an EST (clone ID 32930) belonging to this same uni-
gene cluster was found to be significantly higher expressed
in BRCA1-associated ovarian cancers compared to spo-
radic tumors (Fig. 1D). As such this gene may be one
potentially important target of BRCA1 regulation of gene
expression from the X chromosome. There was no other
overlap between the list of genes differentially expressed
following BRCA1 expression in HCC1937 cells and the
list of genes differentially expressed between BRCA1-asso-
ciated and sporadic ovarian cancers. The lack of a broader
overlap between the list of genes repressed following
BRCA1 expression in the HCC1937 and those differen-
tially expressed between BRCA1-associated and sporadic
ovarian cancers is notable. This signifies that BRCA1's
influence over transcription is unlikely to be gene specific
and rather may involve more global influences over tran-
scription such chromatin remodeling and changes in
methylation states.
BRCA1 expression led to the down regulation of several
ESTs homologous to PAGE-5, a member of the cancer-tes-
tis antigen group of genes (MAGE, GAGE, PAGE, etc.).
These ESTs are likely to represent as yet undiscovered
members of this family of genes that are known for their
characteristic pattern of expression, usually limited to the
testes and tumors [12,13]. Intriguing parallels exist
between expression characteristics of cancer testis antigens
and expression changes mediated by BRCA1. The vast
majority of cancer-testis antigen genes are located within
discrete loci on the X chromosome [13]. Our results dem-
onstrate that BRCA1 represses the expression of clusters of
genes on Xp11, Xp21-p22, Xq13, and Xq26-q28 (Table 1),
which correspond to the genomic location of several
major cancer testis antigen gene clusters [12,13]. Further-
more, high expression of BRCA1 in pachytene spermatids
[14,15] correlates with a significant down regulation of at
least one cancer testis antigen, MAGE-B4 [16]. Finally,
recent reports have documented the aberrant expression
of several cancer-testis antigens in a significant portion of
ovarian cancers and linked their expression to drug-resist-
ance [17,18].
Although not completely understood, the expression of
cancer testis antigens is thought to be, at least partially reg-
ulated by DNA methylation [12]. These data point to
changes in DNA methylation as another possible mecha-
nism involved in the BRCA1-mediated repression of gene
clusters within the X chromosome. Further investigation
of the sequence and genomic organization of genes in
these loci will be useful for elucidating features responsi-
ble for the co-regulation of these genes.
Adenovirus-mediated BRCA1 expression in HCC1937 cells Figure 3
Adenovirus-mediated BRCA1 expression in HCC1937 cells.
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Discussion
Whether any of these BRCA1-regulated X chromosome
genes are involved in ovarian carcinogenesis and / or
tumor progression remains to be determined. However,
several lines of evidence support a possible connection
between the X chromosome and ovarian neoplasia. First,
the loss of a number of regions in the X-chromosome has
been associated with ovarian agenesis or premature ovar-
ian failure, which are commonly observed in Turner syn-
drome and related disorders [19,20]. Thus, the X
chromosome is likely to contain genes involved in ovar-
ian maintenance [19]. Aberrant overexpression of such
potential ovarian survival/growth regulators on the X
chromosome through a mechanism involving the loss of
BRCA1 may be involved in ovarian carcinogenesis and/or
tumor progression. Chromosome X alterations have been
reported in sporadic ovarian carcinomas and borderline
tumors [21,22]. Non-random X inactivation has been
reported in populations of hereditary ovarian and breast
cancer syndrome patients including BRCA1 mutation car-
riers [23,24]. Finally, in a comparison of gene expression
between matched primary and recurrent chemoresistant
ovarian cancer samples from the same patient XIST was
the most differentially expressed gene and its expression
was negatively correlated with response to paclitaxel
chemotherapy [25].
Until recently, a mechanistic explanation for how BRCA1
may affect the expression of multiple genes on the X chro-
mosome was lacking. Evidence for the existence of one
such mechanism has been provided by Ganesan and col-
leagues who have demonstrated the co-localization and
interaction between XIST and BRCA1 [3]. This interaction
was shown to be sufficient and necessary to repress the
expression of a green fluorescent protein transgene intro-
duced into the inactive X chromosome. Our investigation
shows that genes endogenous to the X chromosome are
also repressed by BRCA1 and that genes on certain loci are
preferentially affected. The exact nature of this interaction
and possible differential effects on gene expression from
various regions of the X chromosome remain to be deter-
mined. It is unclear whether BRCA1's effect involves
changes in XIST RNA expression. Ganesan et al. did not
observe such an effect, but other investigators have
reported a two-fold increase in XIST RNA levels following
BRCA1 expression [26]. Using an X chromosome
enriched microarray that has previously been shown to be
able to detect changes in XIST expression associated in X
chromosome polysomies [4], no increase in XIST RNA
was observed following BRCA1 expression. BRCA1 may
target XIST in such a way as to bring about changes in the
expression of various loci on the X chromosome. It is also
possible that BRCA1 may be acting independent of XIST
through a different mechanism such regulation of DNA
methylation. Alterations in DNA methylation play an
Table 1: X chromosome genes showing two-fold or greater change following BRCA1 expression in HCC1937 BRCA1-null cells.
Name Clone ID* Locus Unigene Fold repression Comments
LOC139135 C03503 Xq28 Hs.160594 11.6 Similar to CLOCK protein
EST 32930 Xp11 Hs.99070 8.9
EST 34280 Xp11.2 Hs.99070 8.5
CSTF2 1705354 Xq22.1 Hs.693 5.5
EST 1535341 Xq13 Hs.444962 5.4
EST 1614299 Xq13 Hs.197801 4.3
JM11 1913391 Xp11.23 Hs.417068 3.5
ZNF6 1564783 Xq13 Hs.326801 3.0
ZNF6 5201496 Xq13 Hs.326801 2.4
LOC158572 2070337 Xp11.23 Hs.408191 2.8
LOC158572 1880263 Xp11.2 Hs.408191 2.4
LOC158572 470925 Xp11.23 Hs.408191 2.1
EST 4402168 Xq26 Hs.175894 2.6
KLF8 2148451 Xp11.21 Hs.411296 2.5
KLF8 2148451 Xp11.21 Hs.411296 2.3
EST 2516780 Xp11.23 Hs.293317 2.4 Moderately similar to PAGE-5 protein
EST 2659258 Xq28 Hs.312560 2.2
ED1 2030638 Xq12-q13 Hs.105407 2.2 Weakly similar to PAGE-5 protein
TIMP1 172210 Xp11.23 Hs.446641 2.1
EST 2111889 Xp11.23 Hs.163473 2.0 Weakly similar to XAGE-5 protein
FLJ23614 1938584 Xq26 Hs.28780 1.9
*Integrated Molecular Analysis of Genomes and their Expression (I.M.A.G.E.) Consortium cDNA clone identification.Publish with BioMed Central    and   every 
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integral role in the normal process of X chromosome inac-
tivation and are also involved in the characteristic expres-
sion of cancer-testis antigens most of which reside on the
X chromosome as discussed above.
One of the unexplained features of germ-line BRCA1
mutations is the overwhelmingly disproportionate risk of
cancer in female carriers. One hypothesis put forth to
explain this observation is that estrogen is the inciting
event by leading to deregulated proliferation and carcino-
genesis in hormonally responsive tissues [27]. An alterna-
tive, non-mutually exclusive, hypothesis is that the
deregulated expression of an X-linked gene normally
under BRCA1 control may play a role in predisposing
women to carcinogenesis. This a plausible scenario if
BRCA1 proves to be involved in the process of X-chromo-
some inactivation and /or gene dosage regulation for
those genes on the X chromosome that do not undergo
inactivation. Accordingly, the lack of a need for X chromo-
some inactivation and X-linked gene dose adjustment in
men may explain why male BRCA1 mutation carriers do
not have the same increased risk for cancers. Future stud-
ies will be aimed at testing these hypotheses.
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